Objective To investigate the therapeutic effect and side effect of paclitaxel liposome combined with nedaplat on patients with non-small cell lung cancer( NSCLC ). Methods 74 patients with NSCLC were randomly divided into observation group and control group,37 cases in each group. Patients in observation group were treated by paclitaxel liposome combined with nedaplat, and patients in control group were treated by paclitaxel liposome combined with cisplatin. Every 21 days was one cycle, after 2 cycles of chemotherapy evaluated the therapeutic effect and side effect of both groups. Results The total effective rate of observation group was 40.54% ,the total effective rate of control group was 43. 24% , and there were no significant differences between the two groups( P > 0. 05 ). The major adverse effects were leukopenia followed by vomitus and rash. The incidences of all adverse effects were no significant differences between the two groups( P >0.05 ). Conclusion Paclitaxel liposome and nedaplat is an effective treatment regimen for NSCLC patients.%目的 分析研究紫杉醇脂质体联合奈达铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效和不良反应.方法 将74例NSCLC初治患者随机分为观察组和对照组各37例,观察组给予奈达铂联合紫杉醇脂质体治疗,对照组给予顺铂联合紫杉醇脂质体治疗,21 d为1个周期,2个周期后评价疗效及不良反应.结果 观察组总有效率为40.54%,对照组总有效率为43.24%,两组疗效比较差异无统计学意义(P＞0.05);两组主要不良反应为白细胞减少,其次为呕吐和皮疹,两组所有不良反应差异均无统计学意义(P＞0.05).结论 紫杉醇脂质体联合奈达铂是治疗NSCLC的有效方法.
展开▼
